The technology to be acquired facilitates rapid assay development and reduced costs for the end user.
Co-Diagnostics president Dwight Egan said, "With this technology, we believe our highly efficient assay development capability, combined with superior results and efficient costs, will result in our unique approach to DNA testing being sought after by developers of powerful diagnostics in a wide range of markets."